DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Revlimid (Lenalidomide) - Published Studies

 
 



Revlimid Related Published Studies

Well-designed clinical trials related to Revlimid (Lenalidomide)

Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. [2012]

Lenalidomide after stem-cell transplantation for multiple myeloma. [2012]

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. [2011.07]

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. [2011.02]

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). [2010.12.23]

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. [2010.11.01]

Distribution of lenalidomide into semen of healthy men after multiple oral doses. [2010.07]

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. [2010.01.01]

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. [2010.01]

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. [2010]

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. [2010]

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. [2010]

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. [2009.11.15]

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. [2009.06]

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. [2008.10]

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. [2007.11.22]

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. [2007.11.22]

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. [2007.08.01]

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. [2006.11.15]

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. [2006.09]

Well-designed clinical trials possibly related to Revlimid (Lenalidomide)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. [2010.05.27]

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. [2010.05.01]

The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. [2009.08]

Other research related to Revlimid (Lenalidomide)

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. [2012]

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. [2012]

Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. [2012]

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. [2011.11.10]

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. [2011.10.28]

Treatment with Lenalidomide does not appear to increase the risk of leukemia progression in lower risk myelodysplastic syndrome with 5q deletion. A comparative analysis by the GFM. [2011.10.11]

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. [2011.10.06]

Role of lenalidomide in the treatment of myelodysplastic syndromes. [2011.10]

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. [2011.10]

Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. [2011.09.01]

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. [2011.09.01]

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. [2011.09.01]

Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. [2011.08.11]

The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. [2011.08]

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. [2011.08]

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. [2011.08]

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. [2011.07.28]

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. [2011.07.21]

Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. [2011.07.11]

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. [2011.07]

Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. [2011]

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. [2011]

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. [2010.10.01]

Myocarditis During Lenalidomide Therapy (November). [2010.09.28]

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). [2010.09.27]

Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. [2010.09.20]

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. [2010.09]

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. [2010.09]

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. [2010.08.15]

Kidney dysfunction during lenalidomide treatment for AL amyloidosis. [2010.08.05]

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. [2010.08]

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. [2010.07.22]

Cost-effectiveness of lenalidomide in multiple myeloma. [2010.06]

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. [2010.05.17]

A case of lenalidomide-induced hypersensitivity pneumonitis. [2010]

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). [2010]

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. [2010]

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. [2010]

Neutrophilic dermatosis complicating lenalidomide therapy. [2009.10]

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. [2009.09.02]

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. [2009.09]

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. [2009.08.27]

Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. [2009.08.25]

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. [2009.07.23]

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. [2009.07.23]

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. [2009.07.16]

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. [2009.07.16]

Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. [2009.06]

Phase I study of oral lenalidomide in patients with refractory metastatic cancer. [2009.06]

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. [2009.06]

Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. [2009.05]

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. [2009.05]

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. [2009.04]

Lenalidomide for the treatment of resistant discoid lupus erythematosus. [2009.03]

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. [2009.01.01]

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. [2009.01]

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. [2009.01]

[Lenalidomide in the treatment of multiple myeloma] [2009]

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. [2008.12.20]

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. [2008.12.01]

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. [2008.10.20]

Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. [2008.10]

Consolidation Therapy with Bortezomib/Lenalidomide/ Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. [2008.10]

Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. [2008.08.14]

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. [2008.07.31]

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. [2008.07]

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. [2008.07]

Treatment of plasma cell dyscrasias with lenalidomide. [2008.07]

Thalidomide and lenalidomide: Mechanism-based potential drug combinations. [2008.07]

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. [2008.06.01]

Lenalidomide therapy for metastatic renal cell carcinoma. [2008.06]

Lenalidomide in the treatment of multiple myeloma: a review. [2008.06]

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. [2008.06]

Lenalidomide and its role in the management of multiple myeloma. [2008.06]

Azotemia associated with use of lenalidomide in plasma cell dyscrasias. [2008.06]

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. [2008.05.20]

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. [2008.05]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014